API-CAT Trial: Extended Reduced-Dose Apixaban Non-Inferior to Full Dose for VTE in Cancer
Key Points: Venous thromboembolism (VTE) is a leading cause of mortality in cancer patients Extended anticoagulation is recommended for cancer patients with VTE,... Read more.
RIVAWAR Trial: Rivaroxaban Is Comparable to Warfarin for Post-MI Left Ventricular Thrombus
Key Points: Left ventricular thrombus (LVT) is a serious complication following heart attacks, particularly STEMIs, and can lead to systemic embolism or stroke.... Read more.
VALOR-HCM: Mavacamten Reduces Long-Term Need for Septal Reduction Therapy in Symptomatic Obstructive HCM
Key Points: In patients with treatment-refractory symptomatic obstructive hypertrophic cardiomyopathy (HCM), invasive septal reduction therapies (SRT)—alcohol... Read more.
HELIOS-B trial – Vutrisiran Reduces Risk of Outpatient Worsening Heart Failure in ATTR-CM in a subgroup analysis
Key Points: Transthyretin amyloidosis (ATTR-CM) is a fatal disease caused by the deposition of misfolded amyloid protein in the heart, leading to heart failure and... Read more.